THE BCL-2 INHIBITOR ABT-263 ATTENUATES INTESTINAL FIBROSIS IN HUMAN INTESTINAL ORGANOIDS AND THE MOUSE S. TYPHIMURIUM MODEL

被引：0
|
作者：
Rodansky, Eva S.
Johnson, Laura
Malamet, Benjamin J.
Huang, Sha
Hazelwood, Lisa
Spence, Jason
Higgins, Peter D.
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
867
引用
收藏
页码：S194 / S194
页数：1
相关论文
共 48 条
  • [1] Effect of ABT-263 on Intestinal Fibrosis in Human Myofibroblasts, Human Intestinal Organoids, and the Mouse Salmonella typhimurium Model
    Johnson, Laura A.
    Rodansky, Eva S.
    Tran, Anhdao
    Collins, Stephen G.
    Eaton, Kathryn A.
    Malamet, Benjamin
    Steiner, Calen A.
    Huang, Sha
    Spence, Jason R.
    Higgins, Peter D. R.
    INFLAMMATORY BOWEL DISEASES, 2022, 28 (02) : 161 - 175
  • [2] CB6, A NOVEL GUT-SELECTIVE BCL-2 INHIBITOR, ATTENUATES INTESTINAL FIBROSIS IN MYBFIBROBLAST CELL MODELS AND THE MOUSE S. TYPHIMURIUM MODEL OF INTESTINAL FIBROSIS
    Feng, Yongjia
    Johnson, Laura
    Zhang, Meng
    Collins, Stephen
    Wang, Shaomeng
    Higgins, Peter D.
    GASTROENTEROLOGY, 2021, 160 (06) : S78 - S78
  • [3] ABT-263 Bcl-2 Inhibitor Apoptosis Inducer Oncolytic
    Wang, Y.
    Castaner, R.
    Bolos, J.
    DRUGS OF THE FUTURE, 2008, 33 (10) : 829 - 837
  • [4] ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
    Tse, Christin
    Shoemaker, Alexander R.
    Adickes, Jessica
    Anderson, Mark G.
    Chen, Jun
    Jin, Sha
    Johnson, Eric F.
    Marsh, Kerman C.
    Mitten, Michael J.
    Nimmer, Paul
    Roberts, Lisa
    Tahir, Stephen K.
    Mao, Yu
    Yang, Xiufen
    Zhang, Haichao
    Fesik, Stephen
    Rosenberg, Saul H.
    Elmore, Steven W.
    CANCER RESEARCH, 2008, 68 (09) : 3421 - 3428
  • [5] An efficient synthesis of ABT-263, a novel inhibitor of antiapoptotic Bcl-2 proteins
    Wang, Guangjun
    Zhang, Hushan
    Zhou, Jing
    Ha, Chengyong
    Pei, Duanqing
    Ding, Ke
    SYNTHESIS-STUTTGART, 2008, (15): : 2398 - 2404
  • [6] ABT-263: An orally bloavailable small molecule inhibitor of Bcl-2 family proteins
    Elmore, S.
    EJC SUPPLEMENTS, 2006, 4 (12): : 143 - 143
  • [7] Bcl-2 family inhibitor ABT-263 shows significant but reversible thrombocytopenia in mice.
    Shoemaker, Alex R.
    Mitten, Michael J.
    Adickes, Jessica
    Oleksijew, Anatol
    Zhang, Haichao
    Bauch, Joy
    Marsh, Kennan
    Frost, David J.
    Madar, David
    Tse, Christin
    Fesik, Stephen W.
    Rosenberg, Saul H.
    Elmore, Steven W.
    BLOOD, 2006, 108 (11) : 329A - 329A
  • [8] Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
    Lagadinou, Eleni D.
    Sach, Alexander
    Callahan, Kevin P.
    Rossi, Randall M.
    Neering, Sarah
    Pei, Shanshan
    O'Dwyer, Kristen
    Liesveld, Jane L.
    Brookes, Paul S.
    Becker, Michael W.
    Jordan, Craig T.
    BLOOD, 2012, 120 (21)
  • [9] The Bcl-2/Bcl-xL Inhibitor ABT-263 Attenuates Retinal Degeneration by Selectively Inducing Apoptosis in Senescent Retinal Pigment Epithelial Cells
    Ryu, Wonseon
    Park, Chul-Woo
    Kim, Junghoon
    Lee, Hyungwoo
    Chung, Hyewon
    MOLECULES AND CELLS, 2023, 46 (07) : 420 - 429
  • [10] Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies
    Wilson, Wyndham H.
    O'Connor, O.
    Czuczman, Myron S.
    LaCasce, Ann
    Gerecitano, J.
    Leonard, John P.
    Tulpule, Anil
    Xiong, Hao
    Chiu, Yi-Lin
    Busman, Todd
    Knight, Raymond A.
    Enschede, Sari
    Krivoshik, Andrew
    Humerickhouse, Rod
    BLOOD, 2008, 112 (11) : 734 - 734
12345